Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3212]

$ASH 2018: Longer term data validate durable responses with tisagenlecleucel in adults with relapsed and refractory DLBCL$

ASH 2018: Longer term data validate durable responses with tisagenlecleucel in adults with relapsed and refractory...

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of leukaemia

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of...

ASH 2018: CAR T-Cell therapies show durable responses, new research also explores combination therapies to extend and enhance treatment responses

ASH 2018: CAR T-Cell therapies show durable responses, new research also explores combination therapies to extend...

ASH 2018: Two studies suggest luspatercept reduces need for blood transfusions

ASH 2018: Two studies suggest luspatercept reduces need for blood transfusions

ASH 2018: Four cycles of chemotherapy as effective as six for diffuse large B-Cell lymphoma

ASH 2018: Four cycles of chemotherapy as effective as six for diffuse large B-Cell lymphoma

ASH 2018: Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukaemia

ASH 2018: Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukaemia

$ASH 2018: Alvocidib shows encouraging activity in patients with MCL-1 dependent relapsed or refractory AML$

ASH 2018: Alvocidib shows encouraging activity in patients with MCL-1 dependent relapsed or refractory AML

Sugar supplement slows tumor growth and can improve cancer treatment

Sugar supplement slows tumor growth and can improve cancer treatment

New mechanism controlling the master cancer regulator uncovered

New mechanism controlling the master cancer regulator uncovered

Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies

Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no...

More from ecancer